212 related articles for article (PubMed ID: 36852672)
1. The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer.
Xie H; Ruan G; Wei L; Deng L; Zhang Q; Ge Y; Song M; Zhang X; Lin S; Liu X; Yang M; Song C; Zhang X; Shi H
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):869-878. PubMed ID: 36852672
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory burden as a prognostic biomarker for cancer.
Xie H; Ruan G; Ge Y; Zhang Q; Zhang H; Lin S; Song M; Zhang X; Liu X; Li X; Zhang K; Yang M; Tang M; Song CH; Shi H
Clin Nutr; 2022 Jun; 41(6):1236-1243. PubMed ID: 35504166
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive comparative analysis of prognostic value of serum systemic inflammation biomarkers for colorectal cancer: Results from a large multicenter collaboration.
Xie H; Ruan G; Wei L; Zhang H; Ge Y; Zhang Q; Song M; Zhang X; Liu X; Lin S; Yang M; Hu C; Tang M; Deng L; Hu W; Shi H
Front Immunol; 2022; 13():1092498. PubMed ID: 36685502
[TBL] [Abstract][Full Text] [Related]
4. The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy.
Zhang Y; Chen Z; Jin F; Guo D; Chen Q; Liu Z; Ji S; Gao G
Mediators Inflamm; 2021; 2021():2910892. PubMed ID: 34744510
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive comparison of the prognostic value of systemic inflammation biomarkers for cancer cachexia: a multicenter prospective study.
Xie H; Ruan G; Wei L; Zhang H; Ge Y; Zhang Q; Lin S; Song M; Zhang X; Liu X; Yang M; Tang M; Song CH; Deng L; Shi H
Inflamm Res; 2022 Nov; 71(10-11):1305-1313. PubMed ID: 35962796
[TBL] [Abstract][Full Text] [Related]
6. The prognostic value of the combination of body composition and systemic inflammation in patients with cancer cachexia.
Xie HL; Ruan GT; Wei L; Zhang Q; Ge YZ; Song MM; Zhang X; Lin SQ; Liu XY; Zhang XW; Li XR; Zhang KP; Hu CL; Yang M; Tang M; Song CH; Cong MH; Weng M; Li ZN; Li W; Wang KH; Shi HP
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):879-890. PubMed ID: 36872512
[TBL] [Abstract][Full Text] [Related]
7. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review.
Jafri SH; Shi R; Mills G
BMC Cancer; 2013 Mar; 13():158. PubMed ID: 23530866
[TBL] [Abstract][Full Text] [Related]
8. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
[TBL] [Abstract][Full Text] [Related]
9. Down-regulated MicroRNA 148b expression as predictive biomarker and its prognostic significance associated with clinicopathological features in non-small-cell lung cancer patients.
Ghasemkhani N; Shadvar S; Masoudi Y; Talaei AJ; Yahaghi E; Goudarzi PK; Shakiba E
Diagn Pathol; 2015 Sep; 10():164. PubMed ID: 26377406
[TBL] [Abstract][Full Text] [Related]
10. Systemic Immune-inflammation Index Predicts Survival of Patients After Curative Resection for Non-small Cell Lung Cancer.
Tomita M; Ayabe T; Maeda R; Nakamura K
In Vivo; 2018; 32(3):663-667. PubMed ID: 29695576
[TBL] [Abstract][Full Text] [Related]
11. Relationship between plasma circulating cell-free DNA concentration and treatment outcomes including prognosis in patients with advanced non-small cell lung cancer.
Peng WW; Liu Y; Sha HH; Wen SD; Fang Y; Zhou GR
BMC Pulm Med; 2023 Sep; 23(1):348. PubMed ID: 37710221
[TBL] [Abstract][Full Text] [Related]
12. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
14. Cancer-elicited inflammation attenuates response and outcome in tyrosine kinase inhibitor naive patients with advanced NSCLC.
Ying HQ; Liao YC; Luo YR; Xiong G; Huang Y; Nie RW; Xiong CF; Cheng XX
Pharmacol Res; 2021 Aug; 170():105734. PubMed ID: 34157424
[TBL] [Abstract][Full Text] [Related]
15. The Prognostic Role of Blood Inflammatory Biomarkers and EGFR Mutation Status in Stage IIIA/N2 Non-Small Cell Lung Cancer Patients Treated With Trimodality Therapy.
Yang H; Wang K; Li B; Li S; Li Y; Yuan L
Front Oncol; 2021; 11():707041. PubMed ID: 34917497
[TBL] [Abstract][Full Text] [Related]
16. Effect of C-reactive protein/albumin ratio on prognosis in advanced non-small-cell lung cancer.
Ni XF; Wu J; Ji M; Shao YJ; Xu B; Jiang JT; Wu CP
Asia Pac J Clin Oncol; 2018 Dec; 14(6):402-409. PubMed ID: 30178541
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
Wang J; Liu Y; Mi X; Shao M; Liu L
Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
[TBL] [Abstract][Full Text] [Related]
18. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value.
Srdic D; Plestina S; Sverko-Peternac A; Nikolac N; Simundic AM; Samarzija M
Support Care Cancer; 2016 Nov; 24(11):4495-502. PubMed ID: 27236439
[TBL] [Abstract][Full Text] [Related]
19. High systemic immune-inflammation index is a predictor of poor prognosis in patients with nonsmall cell lung cancer and bone metastasis.
Xu S; Cao S; Yu Y
J Cancer Res Ther; 2021 Dec; 17(7):1636-1642. PubMed ID: 35381733
[TBL] [Abstract][Full Text] [Related]
20. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
[No Abstract] [Full Text] [Related]
[Next] [New Search]
